Recombinant Human CD59 Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 1987-CD

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
1987-CD-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

NS0

Accession #

P13987

Conjugate

Unconjugated

Applications

Bioactivity

View all CD59 Proteins and Enzymes »

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human CD59 protein
Leu26-Asn102, with a C-terminal 10-His tag

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.01 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Starts at Leu26

Predicted Molecular Mass

10.3 kDa

SDS-PAGE

10-20 kDa, reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
When recombinant human C9 is coated at 5 μg/mL (100 μL/well), the concentration of Recombinant Human CD59 that produces 50% optimal binding response is 0.6‑3 μg/mL.

Formulation, Preparation and Storage

1987-CD
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 100 μg/mL in PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CD59

CD59, also known as membrane attack complex inhibition factor (MACIF) and Protectin, is an approximately 20 kDa GPI‑anchored glycoprotein that is an important regulator of the complement system in blood. The complement system triggers innate immune responses to immune complexes, MBL‑opsonized microorganisms, and apoptotic cells through the classical, lectin, and alternative pathways. One major consequence of complement activation is the assembly of a membrane attack complex (MAC) composed of one molecule each of complement proteins C5b, C6, C7, and C8 (C5b‑8) followed by the incorporation of multiple copies of C9 (C5b‑9). Membrane insertion of the MAC results in formation of a cytolytic pore in the target cell (1). CD59, which is widely expressed on healthy cells, binds to both C8 and C9 and shields them from complement‑mediated lysis. It inhibits MAC pore formation by blocking C5b‑8 complex membrane insertion and the incorporation of C9 molecules (2‑4). The binding of CD59 to C8 and C9 is species‑selective, and this contributes to the restricted ability of MACs to lyse cells of other species (5). The cytoprotective function of CD59 plays a variety of roles in pathology. It limits tissue damage and inflammation following ischemia/reperfusion injury (6, 7). It also protects against the development of atherosclerosis and abdominal aortic aneurysms (8, 9). Its protectiveness can be inactivated by diabetes‑induced glycation, leading to increased MAC deposition and hemolytic anemia (10). In contrast, CD59 can be exploited to promote red cell lysis; it functions as a cellular receptor for the bacterial pore‑forming toxin Intermedilysin (11). CD59 can be incorporated into several enveloped viruses such as hepatitis C virus where it limits the destruction of virus particles (12). Aside from its complement regulatory functions, CD59 limits the activation of T cells following their interaction with antigen presenting cells (13), but it promotes NK cell activation through association with NKp30 and NKp46 (14). In mouse, gene duplication has given rise to two related proteins, CD59a and CD59b. Mature human CD59 shares 37%, 43%, and 44% amino acid sequence identity with mouse CD59a, mouse CD59b, and rat CD59, respectively (15).

References

  1. Ricklin, D. et al. (2010) Nat. Rev. Immunol. 11:785.
  2. Farkas, I. et al. (2002) J. Physiol. 539:537.
  3. Meri, S. et al. (1990) Immunology 71:1.
  4. Rollins, S.A. and P.J. Sims (1990) J. Immunol. 144:3478.
  5. Rollins, S.A. et al. (1991) J. Immunol. 146:2345.
  6. Turnberg, D. et al. (2004) Am. J. Physiol. 165:825.
  7. Zhang, J. et al. (2011) Am. J. Pathol. 179:2876.
  8. Wu, G. et al. (2009) Circ. Res. 104:550.
  9. Wu, G. et al. (2010) Circulation 121:1338.
  10. Acosta, J. et al. (2000) Proc. Natl. Acad. Sci. USA 97:5450.
  11. Giddings, K.S. et al. (2004) Nat. Str. Mol. Biol. 11:1173.
  12. Amet, T. et al. (2012) Hepatology 55:354.
  13. Xie, X.-H. et al. (2012) Cell. Immunol. 274:1.
  14. Marcenaro, E. et al. (2003) Eur. J. Immunol. 33:3367.
  15. Sugita, Y. et al. (1989) J. Biochem. 106:555.

Alternate Names

CD59, HRF20, MACIF, MIC11, Protectin

Entrez Gene IDs

966 (Human)

Gene Symbol

CD59

UniProt

P13987

Additional CD59 Products

Product Documents for Recombinant Human CD59 Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human CD59 Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.